Opinion
MISC. CASE NO. 6:17-mc-00117
07-05-2017
SHARON M. ASP-MAYTASH AS SUCCESSOR OF THE ESTATE OF SVEND ASP v. TAKEDA PHARMACEUTICALS U.S.A, INC. AND TAKEDA PHARMACEUTICAL COMPANY LIMITED
JUDGE DOHERTY
REPORT AND RECOMMENDATIONS ON UNOPPOSED MOTION FOR SETTLEMENT AS TO CLAIMS OF DECEDENT , SVEND ASP
This Court, having reviewed Plaintiff's Unopposed Motion to Approve Settlement as to Claims of Sharon M. Asp-Maytash, as Successor and Derivative Claimant; and Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals U.S.A., Inc. (collectively "Takeda"), the parties having received due notice of and having had the opportunity to be heard, and this Court having considered all submissions made, I recommend to the Court that the Motion be
GRANTED and
The settlement by and between Plaintiff, Sharon M. Asp-Maytash, as Successor and Derivative Claimant; individually and as legal heir to the Estate of Svend Asp, deceased, and Takeda, as notice to the Court on June 30, 2017 be
APPROVED.
The Court has jurisdiction of this matter by virtue of the Plaintiffs participating in the Actos MDL Master Settlement Agreement.
ANY PARTY OBJECTING TO THIS RECOMMENDATION SHALL SUBMIT OBJECTIONS, IN WRITING, DIRECTLY TO JUDGE DOHERTY'S CHAMBERS - AND SHALL NOT FILE THE OBJECTION INTO THE RECORD - NO LATER THAN TEN (10) DAYS AFTER ENTRY OF THIS RECOMMENDATION.
If there is no objection within ten (10) days of the entry of this Recommendation, the Recommendation will become an Order.
This is DONE AND SIGNED in Lafayette, Louisiana, this 5th of July 2017.
/s/_________
HONORABLE PATRICK J. HANNA
UNITED STATES MAGISTRATE JUDGE